Short answer
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed an 8-K current report with the SEC on April 3, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Kimberly J. Popovits elected non-employee Class II director, effective April 1, 2026.
RHYTHM PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Kimberly J. Popovits elected non-employee Class II director, effective April 1, 2026
- Popovits’ term runs through the 2028 annual meeting, supporting board continuity
- Edward T. Mathers resigned April 1, 2026, without disagreements involving operations, policies, or practices
- Popovits receives standard non-employee director compensation and indemnification terms
Item 7.01 · Regulation FD Disclosure
- Board transition: Ms. Popovits elected as director and Mr. Mathers resigned
- Governance change may affect board oversight and strategic direction
- Details of the announcement are contained in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RHYTHM PHARMACEUTICALS, INC. 8-K filings
Get the next RYTM 8-K as it lands
Follow RYTM for push alerts, or ask the research agent what this filing means.